Scripps Research Institute
Xenetic Biosciences Extends Drug Development Pact With Scripps Research Institute
The partners are advancing a pipeline of engineered DNase I therapies designed to work with CAR T cells to kill tumor cells.
AbbVie Extends License Deal With Scripps Research's Calibr-Skaggs for Switchable CAR-T Platform
AbbVie will develop cell therapies for solid tumors and autoimmune diseases, as it maintains exclusive access to the platform for five years.